梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TEVA 梯瓦制药

休市中 10-30 16:00:00 EDT

42.09

+0.62

+1.50%

盘后42.21

+0.12+0.30%

19:55 EDT

最高42.59	最低41.17	成交量735.79万
今开41.17	昨收41.47	日振幅3.42%
总市值490.35亿	流通市值457.52亿	总股本11.65亿
成交额3.09亿	换手率0.68%	流通股本10.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TEVA","market":"US","secType":"STK","nameCN":"梯瓦制药","latestPrice":42.09,"timestamp":1793390400000,"preClose":41.47,"halted":0,"volume":7357870,"hourTrading":{"tag":"盘后","latestPrice":42.2148,"preClose":42.09,"latestTime":"19:55 EDT","volume":576784,"amount":24276925.2268,"timestamp":1793404521323,"change":0.1248,"changeRate":0.002965,"amplitude":0.009667},"delay":0,"changeRate":0.014950566674704716,"floatShares":1087000000,"shares":1165000000,"eps":0.6,"marketStatus":"休市中","change":0.62,"latestTime":"10-30 16:00:00 EDT","open":41.17,"high":42.59,"low":41.17,"amount":308638571.54936,"amplitude":0.034242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.6,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"NYSE","adjPreClose":41.47,"preHourTrading":{"tag":"盘前","latestPrice":41,"preClose":41.47,"latestTime":"09:22 EDT","volume":41605,"amount":1705974.33235,"timestamp":1793366548894,"change":-0.47,"changeRate":-0.011333,"amplitude":0.012057},"postHourTrading":{"tag":"盘后","latestPrice":42.2148,"preClose":42.09,"latestTime":"19:55 EDT","volume":576784,"amount":24276925.2268,"timestamp":1793404521323,"change":0.1248,"changeRate":0.002965,"amplitude":0.009667},"volumeRatio":1.3382742802807703,"impliedVol":0.4482,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/TEVA","defaultTab":"news","newsList":[{"id":"1124797283","title":"财报前瞻 | 梯瓦制药本季度营收预计减2.81%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1124797283","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124797283?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:27","pubTimestamp":1793060870,"startTime":"0","endTime":"0","summary":"梯瓦制药将于2026年11月03日美股盘前发布最新季度财报，市场聚焦新品放量及盈利修复路径。市场一致预期本季度公司营收约42.31亿美元，同比-2.81%；调整后每股收益约0.72美元，同比+9.20%；EBIT约11.47亿美元，同比+0.51%。关于毛利率与净利润或净利率的具体预测未获取，未能纳入本节。上一季度公司营收41.42亿美元，同比-0.81%；毛利率51.98%；归母净亏损5.76亿美元，净利率-13.91%；调整后每股收益0.02美元，同比-96.97%。机构观点以看多为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 梯瓦制药本季度营收预计减2.81%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189732481","title":"异动解读｜梯瓦制药盘中上涨5.05%，FDA批准WELTRUZA治疗精神分裂症","url":"https://stock-news.laohu8.com/highlight/detail?id=1189732481","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189732481?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:36","pubTimestamp":1791552965,"startTime":"0","endTime":"0","summary":"10月9日，梯瓦制药盘中上涨5.05%，报41.22美元/股，成交额9075.84万美元。消息面上，美国FDA批准了该公司WELTRUZA用于成人精神分裂症治疗，该药为奥氮平长效皮下注射剂，每月一次给药，无需负荷剂量、口服补充或注射后监测，预计将在未来几周内在美上市。此次批准基于其Solaris III期试验，数据显示疾病严重程度显著降低，个人与社会功能改善。此前，TD Cowen于10月1日对梯瓦制药给出买入评级，目标价55美元，反映市场对其创新管线和生物类似药商业化的持续关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药盘中上涨，FDA批准精神分裂症新药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672753398","title":"三星生物制药与梯瓦制药扩大战略合作，推进至多六款候选生物类似药研发.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672753398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672753398?lang=zh_cn&edition=full","pubTime":"2026-10-01 16:30","pubTimestamp":1790843422,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4557","BK4588","EMXC","LU2322448791.USD","LU2322448957.HKD","LU2473716301.USD","PPH","LU1983299246.USD","IBB","BK4566","LU1992135399.USD","BBP","IBBQ","BK4007","BK4584","LU2324357040.USD","TEVA","MRNX","LU2272731865.HKD","LU1992135472.HKD","IE00B5TLWC47.USD","LU2272731600.USD","MRNY","LU2272731782.SGD","BK4559","XPH","BK4585","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173476954","title":"梯瓦制药新数据：Uzedy®（利培酮）长效针剂在精神分裂症治疗依从性上优于同类药物，同时降低急诊与医疗成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1173476954","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173476954?lang=zh_cn&edition=full","pubTime":"2026-09-19 04:32","pubTimestamp":1789763533,"startTime":"0","endTime":"0","summary":"梯瓦制药最新公布的现实世界研究数据引发行业关注。数据显示，其旗下Uzedy（利培酮）长效注射剂在帮助精神分裂症患者维持治疗方面，表现出优于其他同类长效针剂的显著成效——不仅大幅提升患者持续用药率，还同步压低了急诊就医频次及整体医疗开支。梯瓦制药此番公布的数据，不仅是对自家产品疗效的背书，更是在为长效针剂在精神分裂症治疗版图中的定位加码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1983299246.USD","BK4557","BK4007","BK4566","BK4584","BK4585","TEVA","LU2324357040.USD","BK4596","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181129883","title":"异动解读｜梯瓦制药盘中上涨5.07%，普通股正式登陆纽交所直接交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1181129883","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181129883?lang=zh_cn&edition=full","pubTime":"2026-09-15 00:27","pubTimestamp":1789403232,"startTime":"0","endTime":"0","summary":"9月15日，梯瓦制药盘中上涨5.07%，报38.97美元/股，成交额3820.02万美元。消息面上，梯瓦制药宣布其普通股已正式在纽约证券交易所开始直接交易，完成从美国存托凭证向普通股的转换，股票代码继续为\"TEVA\"，同时在纽交所和特拉维夫交易所双重上市。公司表示，此举有望扩大投资者准入渠道并强化其在美国资本市场的地位。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药转板纽交所，盘中强势上扬","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560146","title":"梯瓦制药（TEVA）完成49亿美元等值优先票据定价 募资用于置换多笔存量债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560146","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666560146?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:00","pubTimestamp":1789038049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 完成总规模约49亿美元等值优先票据的发行定价。本次发行共分为五个批次：10亿欧元2033年到期票据，票面利率4.25%；5亿欧元2036年到期票据，票面利率4.625%；10亿美元2034年到期票据，票面利率5.5%；10亿美元2037年到期票据，票面利率5.75%；12亿美元2032年到期票据，票面利率5.25%。梯瓦制药计划将本次募资净额，叠加公司现有现金，用于赎回存量债务、支付相关发行费用以及一般企业用途。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BNDW","BK4596","LU2324357040.USD","LU1983299246.USD","BK4584","BK4585","BK4557","BK4007","BK4566","BK4559","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188485546","title":"梯瓦制药美股盘前上涨3.5%，免疫疾病药物中期试验达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1188485546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188485546?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:13","pubTimestamp":1788351207,"startTime":"0","endTime":"0","summary":"梯瓦制药（Teva Pharmaceutical）在美国上市的股票在盘前交易中上涨了3.5%。此前，该公司宣布其治疗免疫系统疾病的药物在中期临床试验中达到了主要目标。这一消息提振了投资者信心，推动股价在盘前时段走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TEVA","BK4585","LU2324357040.USD","BK4566","BK4559","LU1983299246.USD","BK4557","BK4007","BK4584","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811810","title":"梯瓦制药美国上市盘前股价上涨3.5%，此前该公司免疫紊乱药物在中期试验中达到主要终点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664811810?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:11","pubTimestamp":1788351064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1983299246.USD","BK4557","BK4007","BK4584","LU2324357040.USD","TEVA","BK4585","BK4596","BK4559","BK4566","BK4588","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333811","title":"梯瓦制药（TEVA）与Royalty Pharma（RPRX）合作抗体药物TEV'408迎重大临床突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333811","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333811?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:07","pubTimestamp":1788350836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 与Royalty Pharma宣布，双方合作开发的抗白细胞介素-15抗体药物TEV'408在治疗成人乳糜泻的2a期临床试验中取得积极结果。在给药第8周时，与安慰剂组相比，TEV'408在统计学上显著且临床上有效地预防了由麸质诱发的肠道损伤。根据“乳糜泻症状日记”显示，接受TEV'408治疗的患者其胃肠道症状评分明显低于安慰剂组。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4596","BK4007","BK4588","BK4585","PBE","BK4559","TEVA","RPRX","IHE","LU1983299246.USD","BK4566","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120165657","title":"梯瓦制药宣布抗IL-15抗体治疗乳糜泻的2a期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1120165657","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120165657?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:04","pubTimestamp":1788350687,"startTime":"0","endTime":"0","summary":"$梯瓦制药$今日宣布，其正在进行的 2a期临床研究取得积极顶线结果。","market":"us","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药宣布抗IL-15抗体治疗乳糜泻的2a期研究取得积极顶线结果","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1130673950","title":"异动解读｜梯瓦制药盘前上涨5.11%，在研管线TEV-408乳糜泻2a期数据积极叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1130673950","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130673950?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:53","pubTimestamp":1788350014,"startTime":"0","endTime":"0","summary":"9月2日，梯瓦制药盘前上涨5.11%，报37.99美元/股，成交额444.25万美元。消息面上，梯瓦制药宣布其在研抗IL-15单抗TEV-408在2a期临床试验中达到统计学显著性终点，有效预防麸质诱导的肠道损伤，为乳糜泻患者带来新治疗希望，这一突破性数据成为盘前上涨的直接催化剂。多条管线与业务拓展进展同步推进，支撑市场对梯瓦创新转型前景的乐观预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药盘前上涨，乳糜泻新药数据积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141512147","title":"梯瓦制药Tev‘408在2a期研究中显著预防麸质诱导损伤","url":"https://stock-news.laohu8.com/highlight/detail?id=1141512147","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141512147?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:07","pubTimestamp":1788347268,"startTime":"0","endTime":"0","summary":"梯瓦制药宣布，其研发的Tev‘408在2a期临床试验中展现出统计学上显著的预防效果，能够有效阻止麸质引发的肠道损伤。这一研究结果备受关注，为乳糜泻患者带来了新的希望。梯瓦制药的这项突破性进展，不仅验证了Tev‘408的作用机制，更为后续更大规模的临床研究奠定了坚实基础。业内专家指出，这一成果有望为目前缺乏有效治疗手段的乳糜泻患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","TEVA","LU1983299246.USD","BK4588","BK4566","BK4559","BK4585","BK4007","BK4596","BK4584","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103791404","title":"Trailpeak 重磅登场：Teva 首款高性能日常越野跑鞋，携手品牌探险运动员联合打造","url":"https://stock-news.laohu8.com/highlight/detail?id=1103791404","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103791404?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:03","pubTimestamp":1788267798,"startTime":"0","endTime":"0","summary":"Trailpeak 正式亮相——这是 Teva 品牌推出的首款专为日常越野跑打造的高性能跑鞋。该鞋款并非闭门造车，而是与品牌旗下的“探险运动员理事会”深度共创的结晶。从设计理念到功能细节，Trailpeak 都凝聚了这群长期活跃于山野间的运动员的真实反馈与实战经验。Trailpeak 的面世，或许将重新定义“日常越野跑鞋”的标准，成为跑者们鞋柜中值得信赖的新选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","TEVA","BK4567","LU1983299246.USD","BK4559","BK4007","BK4588","STYL","BK4584","LU0266013472.USD","DECK","BK4557","BK4146","BK4585","BK4596","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421155","title":"梯瓦制药的妥瑞氏综合征疗法获美国FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421155","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660421155?lang=zh_cn&edition=full","pubTime":"2026-08-19 23:01","pubTimestamp":1787151678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4566","TEVA","BK4557","BK4584","BK4588","LABU","BK4559","LU1983299246.USD","BK4596","LU2324357040.USD","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660423334","title":"梯瓦制药的Ecopipam新药申请获得美国食品药品监督管理局（FDA）优先审评资格。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660423334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660423334?lang=zh_cn&edition=full","pubTime":"2026-08-19 20:31","pubTimestamp":1787142670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","LU1983299246.USD","BK4557","BK4007","BK4566","BK4584","BK4585","TEVA","LU2324357040.USD","BK4596","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145089165","title":"个股动态汇总：福特、卡特彼勒、梯瓦制药、星巴克","url":"https://stock-news.laohu8.com/highlight/detail?id=1145089165","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145089165?lang=zh_cn&edition=full","pubTime":"2026-07-30 06:45","pubTimestamp":1785365155,"startTime":"0","endTime":"0","summary":"其股价收盘微涨，幅度超过2%。卡特彼勒：该建筑设备制造商的股价却大跌约7%，原因在于市场对数据中心业务感到忧虑，加之贝尔德的分析师下调了其评级。其股价随之大涨，接近10%。公司股价下跌了6%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","LU0868494708.USD","JOYT","EXI","IE00BSNM7G36.USD","LU0251131958.USD","FEBU","03143","BK4559","LU2168563687.JPY","BK4566","CAT","LU2023250504.SGD","BK4597","LU0942090050.USD","LU2106854487.HKD","LU2237438978.USD","BK4588","BK4610","02888","IE00B3T34201.USD","PBJ","BK4555","RGLO","GXDW","GASZ","LU0417517546.SGD","LU0211977185.USD","LU0607220059.USD","LU1548497426.USD","LU1983299246.USD","BK4154","LU0164880469.USD","TEVA","IE0008369823.USD","LU2168564149.EUR","LU1917777945.USD","TRUI","LU0149534421.HKD","LU0882574139.USD","FRDD","LU1093756168.USD","BK1572","BK1231","BK4532","SBU","LU1974910355.USD","SG9999001689.USD","BK4533","PMDE","BK4552","FRDU","LU0320765489.SGD","BK1601","VOTE","BK4504","DB","LU0266013472.USD","SBUX","LU0208291251.USD","BK4520","LU0238689110.USD","IHF","BK4516","LU1988902786.USD","BK4099","LU1093756325.SGD","RSHO","HWAY","LU0390134368.USD","VGFPF","BK4585","HUM","DECU","LU2168564065.EUR","LU1119993845.HKD","SG9999000327.SGD","BK4584","LU1481107354.HKD","BK1619","LU2357305700.SGD","BREW","LU1720051017.SGD","LU0048573561.USD","FXH","LU0251142724.SGD","LU0149721374.USD","SG9999014021.USD","LU0877626530.USD","BK4535","BK4596","LU2168564222.USD","LU0256863811.USD","LU1720051108.HKD","LU0742534661.SGD","SG9999014005.SGD","LU0205439572.USD","LU1983260115.SGD","MADE","LU2543165471.USD","STAN.UK","BK4209","LU0211331839.USD","BK4118","LU0070302665.USD","SG9999014013.SGD","UXI","LU2168564495.EUR","LU1064131342.USD","IE00BD6J9T35.USD","BK4007","LU2324357040.USD","F","LU0823411888.USD","LU2264538146.SGD","BK4149","BK4574","LU0868494617.USD","LU0348723411.USD","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121279366","title":"异动解读｜梯瓦制药盘中上涨6.95%，Q2营收超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1121279366","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121279366?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:37","pubTimestamp":1785332240,"startTime":"0","endTime":"0","summary":"7月29日，梯瓦制药盘中上涨6.95%，报35.11美元/股，成交额8175.83万美元。消息面上，公司发布第二季度财报，营收达41.42亿美元，超出市场预期的40.47亿美元；同时公司上调全年营收指引至165亿至168.5亿美元，高于此前的164亿至168亿美元区间。不过调整后每股收益仅为0.02美元，大幅低于分析师预期。市场更关注营收端的超预期表现及指引上调信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125960505","title":"异动解读 | 梯瓦制药盘中大涨6.47%，Q2营收超预期成主要推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1125960505","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125960505?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:34","pubTimestamp":1785332061,"startTime":"0","endTime":"0","summary":"梯瓦制药（TEVA）今日盘中股价大涨6.47%，引发市场广泛关注。消息面上，公司最新发布的第二季度财报显示，营收达到41.42亿美元，超出市场预期的40.47亿美元，成为支撑股价走高的核心驱动力。尽管调整后每股收益仅为0.02美元，大幅低于分析师预期的0.25美元，但营收端的超预期表现显然更受市场重视。此外，公司近期在生物类似药及创新管线领域持续取得进展，包括Ocrevus生物类似药的全球授权、Eylea生物类似药在欧洲的上市推进，以及ecopipam新药申请的提交等多项利好，也从侧面增强了市场对公司长期增长前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144714689","title":"异动解读 | 梯瓦制药盘前大涨5.15%，Q2营收超预期为主要驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=1144714689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144714689?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:10","pubTimestamp":1785323449,"startTime":"0","endTime":"0","summary":"梯瓦制药（TEVA）今日盘前交易时段股价大涨5.15%，报33.3美元，成交额达85.61万美元，引发市场关注。消息面上，公司发布了第二季度财报，营收达到41.42亿美元，超出市场预期的40.47亿美元。营收端的超预期表现成为支撑盘前股价走高的主要因素。不过，公司调整后每股收益仅为0.02美元，大幅低于分析师一致预期的0.25美元，同比下降约97%。此外，公司近期在生物类似药及创新管线领域持续推进，包括Ocrevus生物类似药全球授权、Eylea生物类似药欧洲上市以及ecopipam新药申请提交等多项进展，也从侧面增强了市场对公司长期发展的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187879949","title":"异动解读｜梯瓦制药盘前上涨5.15%，Q2营收超预期但每股收益大幅不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1187879949","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187879949?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:09","pubTimestamp":1785323379,"startTime":"0","endTime":"0","summary":"7月29日，梯瓦制药盘前上涨5.15%，报33.3美元/股，成交额85.61万美元。消息面上，公司发布第二季度财报，营收41.42亿美元，超出市场预期的40.47亿美元；但调整后每股收益仅为0.02美元，大幅低于分析师一致预期的0.25美元，同比下降约97%。营收端的超预期表现或为盘前股价走高的主要支撑。此前一季度公司同样实现营收与利润双超预期，全年Non-GAAP每股收益指引维持在1.91至2.11美元区间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tevapharm.com;ir.tevapharm.com","stockEarnings":[{"period":"1week","weight":0.068},{"period":"1month","weight":0.0629},{"period":"3month","weight":0.2022},{"period":"6month","weight":0.2043},{"period":"1year","weight":1.1013},{"period":"ytd","weight":0.3486}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性生物制药公司，拥有重要的仿制药业务，在全球约57个市场开展业务。它专注于神经科学和免疫学领域的创新，同时提供复杂的仿制药、生物仿制药和药房品牌，以满足患者的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.063449},{"month":2,"riseRate":0.357143,"avgChangeRate":-0.01732},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.019164},{"month":4,"riseRate":0.357143,"avgChangeRate":0.006451},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00523},{"month":6,"riseRate":0.466667,"avgChangeRate":0.009278},{"month":7,"riseRate":0.6,"avgChangeRate":0.027757},{"month":8,"riseRate":0.266667,"avgChangeRate":-0.042226},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.004542},{"month":10,"riseRate":0.466667,"avgChangeRate":-0.013755},{"month":11,"riseRate":0.642857,"avgChangeRate":0.061945},{"month":12,"riseRate":0.571429,"avgChangeRate":0.030034}],"exchange":"NYSE","name":"梯瓦制药","nameEN":"Teva Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"梯瓦制药,TEVA,梯瓦制药股票,梯瓦制药股票老虎,梯瓦制药股票老虎国际,梯瓦制药行情,梯瓦制药股票行情,梯瓦制药股价,梯瓦制药股市,梯瓦制药股票价格,梯瓦制药股票交易,梯瓦制药股票购买,梯瓦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}